[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy]

Nihon Rinsho. 2005 Nov:63 Suppl 11:438-41.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Amoxicillin / administration & dosage*
  • Anti-Bacterial Agents / administration & dosage*
  • Aryl Hydrocarbon Hydroxylases / genetics
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / metabolism
  • Clarithromycin
  • Cytochrome P-450 CYP2C19
  • Drug Administration Schedule
  • Drug Resistance, Bacterial
  • Drug Therapy, Combination
  • Enzyme Inhibitors / administration & dosage*
  • Enzyme Inhibitors / metabolism
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori*
  • Humans
  • Lansoprazole
  • Metronidazole / administration & dosage
  • Mixed Function Oxygenases / genetics
  • Omeprazole / administration & dosage
  • Omeprazole / analogs & derivatives
  • Omeprazole / metabolism
  • Polymorphism, Genetic
  • Proton Pump Inhibitors*
  • Rabeprazole
  • Treatment Failure

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Bacterial Agents
  • Benzimidazoles
  • Enzyme Inhibitors
  • Proton Pump Inhibitors
  • Lansoprazole
  • Metronidazole
  • Rabeprazole
  • Amoxicillin
  • Mixed Function Oxygenases
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Clarithromycin
  • Omeprazole